First ovarian cancer therapy for ST oncology portfolio Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 Phase 3 results expected in 2025 Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore and Seoul, South Korea, 13 October 2023: Independent
